Our findings suggest that IL-17A derived from lung cancer cells affects osteoclast differentiation by regulating OCP apoptosis, indicating that IL-17A is a potential therapeutic target for cancer-associated bone resorption in patients with lung cancer. Here, IL17A is linked to lung cancer.